Natriuretic peptide in the management of cardiovascular diseases
| dc.contributor.author | Salo, K. | |
| dc.contributor.author | Візір, Марина Олександрівна | |
| dc.contributor.author | Vizir, Maryna | |
| dc.contributor.author | Визир, Марина Александровна | |
| dc.date.accessioned | 2017-12-13T09:39:37Z | |
| dc.date.available | 2017-12-13T09:39:37Z | |
| dc.date.issued | 2017-10 | |
| dc.description.abstract | The quantification of NUP and especially BNP allows not only to exclude the possibility of cardiovascular pathology, but also to confirm this diagnosis., It is possible to determine and correct the approaches to the therapy of CHF, to monitor its effectiveness and to evaluate the further prognosis by the level of BNP in the blood plasma. The effectiveness of the therapy can be analyzed by the dynamics of BNP concentration. It was approved that nesiritide helps to alleviate clinical symptoms, improves the parameters of hemodynamics and cardiac function. | ru_RU |
| dc.identifier.citation | Salo K. Natriuretic peptide in the management of cardiovascular diseases / K. Salo // Relevant issues of modern medicine: the experience of Poland and Ukraine : international research and practice conference, Lublin, October 20–21 2017. – Lublin, 2017. – P. 69–72. | ru_RU |
| dc.identifier.uri | https://repo.knmu.edu.ua/handle/123456789/18816 | |
| dc.language.iso | en | ru_RU |
| dc.publisher | Medical University of Lublin | ru_RU |
| dc.subject | natriuretic peptide | ru_RU |
| dc.subject | nesiritide | ru_RU |
| dc.subject | cardiovascular diseases | ru_RU |
| dc.subject | heart failure | ru_RU |
| dc.title | Natriuretic peptide in the management of cardiovascular diseases | ru_RU |
| dc.type | Article | ru_RU |